VKTX has been in the news 900% more than usual
Jan 07, 2026, 1:33 PM
-5.59%
What does VKTX do
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
VKTX has been in the news recently: Viking Therapeutics will present its therapies for metabolic disorders at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026. The company also appointed Neil Aubuchon as chief commercial officer to improve commercialization strategies for its Phase 3 obesity treatment, VK2735, while facing a short interest of 25.48% of its float.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.